Thinking of joining a study?

Register your interest

NCT04904328 | UNKNOWN | Migraine

A Proof of Concept Alleviating the Symptoms of Photosensitive Migraine.

Mitsui Chemicals, Inc.

Brief Summary:

This proof of concept clinical study will investigate the efficacy of active lens with frame in alleviating the symptoms of migraine which are caused by photosensitivity. The spectacles cut out blue light wavelength and hypothetically alleviate symptoms of migraine and thus either treat or prevent migraine headaches from occurring.

Condition or disease



Lumishade® Active Lens

Lumishade® Sham Lens



Detailed Description:

Patients will be randomised to one of two groups: Group 1 1. Patients wear sham glasses for 4 weeks 2. Patients have 1 week's washout 3. Patients wear active glasses for 4 weeks Group 2 4. Patients wear active glasses for 4 weeks 5. Patients have 1 week's washout 6. Patients wear sham glasses for 4 weeks The study will aim to determine whether wearing the active lens successfully reduces the symptoms of migraine, compared to wearing sham lens. Assuming a fairly conservative SD in the primary endpoint of 8 points, a total of 56 participants would be required to have 90% power to detect a minimum clinically significant difference of 5 points in a two-sample t-test. Allowing for a 20% drop-out rate, 70 participants would need to be recruited. Patients will be in the trial for a total of 13 weeks (4 week run-in, two 4 week periods, with 1 week washout in between).

Estimated Enrollment : 77 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : A Proof of Concept Clinical Investigation Designed to Evaluate the Performance of Lumishade® Lens With Frame in Alleviating the Symptoms of Photosensitive Migraine.
Actual Study Start Date : 2021-06-30
Estimated Primary Completion Date : 2022-01-04
Estimated Study Completion Date : 2022-04-04

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Inclusion Criteria
  • 1. Over 18 years old
  • 2. Diagnosis of migraine before the age of 50, confirmed though screening consultation with the patient
  • 3. Willing and able to provide written informed consent
  • 4. Willing to comply with study assessment schedule and patient diary entry
  • 5. Diagnosis of migraine, with or without aura based on the following primary headache characteristics (based on the Revised International Headache Society criteria for migraine headache)
  • 1. At least 5 attacks fulfilling criteria B-D
  • 2. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)
  • 3. Headache has at least two of the following characteristics
    • i. unilateral location ii. pulsating quality iii. moderate or severe pain intensity iv. aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) d. During headache at least one of the following: i. nausea and/or vomiting ii. photophobia and phonophobia e. Not attributed to another disorder
    • 6. Migraine associated with photophobia i.e. either photic hypersensitivity or photic allodynia or inter-ictal photophobia or migraine triggered by light according to patient or a combination of these 4 factors
    • 7. No expected changes of headache preventative medications after enrolment
    Exclusion Criteria
    • 1. Patients with other light sensitive conditions, such as iritis or retinal disease.
    • 2. Patients who have less than 4 headache days per month
    • 3. Patients who have daily headaches.
    • 4. Pregnant or nursing
    • 5. History of cluster headache or hemiplegic migraine
    • 6. Evidence of seizure or major psychiatric disorder
    • 7. Score of 19 or higher on the BDI
    • 8. Active chronic pain syndrome
    • 9. Cardiac or hepatic disease
    • 10. Have taken any investigational medication within 12 weeks before randomization, or are scheduled to receive an investigational drug
    • 11. Have received Botox injections for any purpose in the head or face region within 3 months of trial onset or scheduled to receive such treatment during the trial
    • 12. Medication overuse as per the revised ICHD-3 IHS criteria
    • 13. Medications that can affect light perception like ethambutol, hydroxychloroquine or amiodarone or any other according to the opinion of the investigator
    • 14. Patients requiring prescription/reading glasses
    • 15. Patients who have not responded to three or more migraine preventive drugs
    • 16. Patients who have a diagnosed neurological disorder that may influence the study according to the investigators

A Proof of Concept Alleviating the Symptoms of Photosensitive Migraine.

Location Details


Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.


No Location Found